Ogier Leman’s team have a track record in acting for Irish and UK financial institutions, alternative finance providers, insolvency practitioners, developers and investors on an asset, portfolio and project financing.
The life sciences industry in Ireland has grown remarkably over the last 20 years and has evolved from the ’90s to a new position of global significance.
The growth has seen Ireland become a natural hub for the MedTech & pharma giants in a similar fashion to the infiltration of the big US data Tech companies. Ireland is now a leading location for pharmaceutical and medical technology companies such as Abbot, Allergan, Boston Scientific, GSK, Lilly, Medtronic, MSD, Novartis, Pfizer and Stryker. Alongside this, an indigenous start-up culture has developed.
The uncertainty around Brexit has affected the Life Sciences & MedTech market particularly in relation to CE Marking and Marketing Authorisation Holders, these issues aside a real opportunity exists also for businesses in this area who wish to expand their presence in the EU-27 remaining member states post-Brexit.
As a major player, Ireland must anticipate these Brexit related changes along with the constant innovation and disruptive technologies in the sector. As Ireland’s tech law firm, Ogier Leman is ideally positioned to help Life Sciences business to capitalise on the opportunities.